Skip to main content
Back
DBVT logo

DBV Technologies S.A.

Data quality: 100%
DBVT
NASDAQ Healthcare Biotechnology
CEO: Daniel Tassé Employees: 106 IPO: Oct 22, 2014
Price
$21.06
Change
▲ $0.56
2.73%
Mkt Cap
503.79M
Day Range
$19.89 $21.33
52-Week Range
$6.00 $26.19
Volume
445,419
50D / 200D Avg
$21.55
$15.04
Prev Close
$20.50

Quick Summary

Key Takeaways

Debt/Equity of 0.13 — conservative balance sheet
Negative free cash flow of -121.18M
PEG of 0.36 suggests growth is underpriced

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-150.29%
Below sector avg (3.46%)
ROIC-60.32%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.13
Below sector avg (0.23)
Current Ratio3.67
Interest Coverage0.00

Valuation

P/E Ratio
-3.42
Below sector avg (0.22)
Forward P/EN/A
P/B Ratio2.99
EV/EBITDAN/A
Dividend Yield0.00%

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (640 peers)

Metric Stock Sector Median
P/E -3.4 0.2
P/B 3.0 2.9
ROE % -150.3 3.5
Net Margin % 3.9
Rev Growth 5Y % 9.6
D/E 0.1 0.2

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -147.40M
ROE -150.29% ROA -63.07%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -121.18M
ROIC -60.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.13 Current Ratio 3.67
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3.42 Forward P/E N/A
P/B Ratio 2.99 P/S Ratio N/A
PEG Ratio 0.36 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -24.05%
Market Cap 503.79M Enterprise Value 331.31M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 15.73M 4.80M 5.71M
Net Income -147.40M -113.72M -72.73M -96.30M -97.81M
EPS (Diluted) -5.30 -5.90 -3.80 -6.20 -8.90
Gross Profit -17.67M -6.81M 15.73M -15.50M -3.57M
Operating Income -153.16M -120.53M -76.43M -96.63M -98.61M
EBITDA -135.49M -110.99M -63.27M -76.68M -91.16M
R&D Expenses 22.78M 89.90M 60.22M 75.50M 70.34M
SG&A Expenses 17.24M 23.81M 31.94M 17.56M 23.83M
D&A 17.67M 6.81M 13.16M 20.30M 8.38M
Interest Expense 0.0 0.0 0.0 427,000.0 690,000.0
Income Tax -5.16M -4.08M 7,000.0 70,000.0 -381,000.0

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 233.72M 65.66M 182.99M 246.52M 146.32M
Total Liabilities 64.95M 38.27M 42.80M 52.07M 47.29M
Shareholders' Equity 168.77M 27.39M 140.19M 194.45M 99.03M
Total Debt 21.68M 7.80M 6.55M 4.15M 10.66M
Cash & Equivalents 194.17M 32.46M 141.37M 209.19M 77.30M
Current Assets 212.94M 44.39M 158.92M 223.07M 114.52M
Current Liabilities 58.03M 31.14M 37.34M 29.52M 31.40M